CancerVax Corporation
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 6, 2005
CANCERVAX CORPORATION
(Exact Name of Registrant as Specified in its Charter)
         
Delaware
(State or Other Jurisdiction
of Incorporation)
  0-50440
(Commission
File Number)
  52-2243564
(IRS Employer
Identification No.)
         
2110 Rutherford Road, Carlsbad, CA
(Address of Principal Executive Offices)
  92008
(Zip Code)
Registrant’s telephone number, including area code: (760) 494-4200
 
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


TABLE OF CONTENTS

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
SIGNATURES


Table of Contents

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
     On September 6, 2005, Martin A. Mattingly, Pharm.D., notified CancerVax Corporation (the “Company”) of his resignation as Executive Vice President and Chief Operating Officer of the Company, effective as of September 13, 2005. Dr. Mattingly, who has indicated that his reason for deciding to resign is to accept a position as President and Chief Executive Officer of another biotechnology company, has served as an executive officer of the Company since 2003.

 


Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  CANCERVAX CORPORATION
 
 
Date: September 9, 2005  By:   /s/ David F. Hale    
    Name:   David F. Hale   
    Title:   President and Chief Executive Officer